{"id":449490,"date":"2024-10-20T09:03:07","date_gmt":"2024-10-20T09:03:07","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/aami-tir10993-20-2006-r2021\/"},"modified":"2024-10-26T16:55:19","modified_gmt":"2024-10-26T16:55:19","slug":"aami-tir10993-20-2006-r2021","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/aami\/aami-tir10993-20-2006-r2021\/","title":{"rendered":"AAMI TIR10993 20 2006 R2021"},"content":{"rendered":"
This standard covers current state of knowledge in the area of immunotoxicology, including information on methods of assessment and their predictive value; to identify what the problems are and how they have been dealt with in the past; and offers advice on how the problems should be addressed in future standards.<\/p>\n
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
1<\/td>\n | AAMI\/ISO TIR10993-20:2006\/(R)2021, Biological evaluation of medical devices – Part 20: Principles and methods for immunotoxicology testing of medical devices <\/td>\n<\/tr>\n | ||||||
2<\/td>\n | Title page <\/td>\n<\/tr>\n | ||||||
3<\/td>\n | Copyright information <\/td>\n<\/tr>\n | ||||||
4<\/td>\n | AAMI technical information report ANSI technical report <\/td>\n<\/tr>\n | ||||||
5<\/td>\n | Contents <\/td>\n<\/tr>\n | ||||||
6<\/td>\n | Glossary of equivalent standards <\/td>\n<\/tr>\n | ||||||
8<\/td>\n | Committee representation <\/td>\n<\/tr>\n | ||||||
10<\/td>\n | Background of AAMI adoption of ISO\/TS 10993-20:2006 <\/td>\n<\/tr>\n | ||||||
11<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
13<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
14<\/td>\n | 1 Scope 2 Normative references 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 4 Risk assessment and risk management <\/td>\n<\/tr>\n | ||||||
16<\/td>\n | 5 Identification of hazards <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 6 Methods of assessment of immunotoxicity 6.1 General <\/td>\n<\/tr>\n | ||||||
19<\/td>\n | 6.2 Inflammation 6.3 Immunosuppression <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 6.4 Immunostimulation 6.5 Hypersensitivity 6.6 Auto-immunity 7 Extrapolation of data provided by pre-clinical assays <\/td>\n<\/tr>\n | ||||||
23<\/td>\n | Annex A (informative) Current state of knowledge A.1 Immunology <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | A.2 Immunotoxicology <\/td>\n<\/tr>\n | ||||||
25<\/td>\n | A.3 Human health consequences of changes in the immune system <\/td>\n<\/tr>\n | ||||||
27<\/td>\n | Annex B (informative) Clinical experience with medical devices <\/td>\n<\/tr>\n | ||||||
29<\/td>\n | Annex C (informative) Flow chart for immunotoxicity testing <\/td>\n<\/tr>\n | ||||||
30<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" AAMI\/ISO TIR10993-20:2006 (R2021) – Biological Evaluation Of Medical Devices – Part 20: Principles And Methods For Immunotoxicology Testing Of Medical Devices<\/b><\/p>\n |